Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol

Fig. 2

Integration of safety data from CONFIDENCE into other global post-marketing safety studies. Safety data from the German study CONFIDENCE will be integrated into the global post-marketing safety studies MANUSCRIPT and VERISMO. MANUSCRIPT (blue) will combine data from CONFIDENCE (orange) and from multiple existing international MS and population registries (Big MS Data Group, BMSD, which combines clinical data from multiple registries, i.e. MSBase, France OFSEP [Observatoire Français de la Sclérose en Plaques], Denmark, Sweden and Italy). VERISMO (purple) will combine prospective data collected at sites in the United States (U.S.) and the German CONFIDENCE sites

Back to article page